# RGL-305+ Lymphoma + Exploratory Clinical Study

> **NCT07006012** · NA · RECRUITING · sponsor: **Fudan University** · enrollment: 12 (estimated)

## Conditions studied

- Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)

## Interventions

- **DRUG:** RGL-305

## Key facts

- **NCT ID:** NCT07006012
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-21
- **Primary completion:** 2028-03-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07006012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07006012, "RGL-305+ Lymphoma + Exploratory Clinical Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07006012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*